Long-term Effects of Hearing Intervention on Brain Health in the Aging and Cognitive Health Evaluation in Elders Randomized Study
The ACHIEVE study represents a landmark trial in the prevention of Alzheimer's disease and cognitive decline through a non-pharmacological intervention. This study investigates whether hearing intervention can slow cognitive decline in older adults with hearing loss, addressing one of the largest modifiable risk factors for dementia[1].
The ACHIEVE randomized trial (2023) demonstrated that hearing intervention slowed cognitive decline by 48% in at-risk older adults over 3 years, representing a breakthrough in dementia prevention strategies[2]. This follow-up study (NCT05532657) extends the observation period to examine longer-term effects.
Alzheimer's disease and cognitive impairment affect millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of these conditions, coupled with the lack of disease-modifying treatments, underscores the critical importance of preventive interventions that target modifiable risk factors[3].
| Parameter | Value |
|---|---|
| NCT Number | NCT05532657 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Johns Hopkins University |
| Enrollment | 629 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2023-01-12 00:00:00 |
| Completion Date | 2026-06-30 00:00:00 |
| Last Updated | 2025-11-10 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[3:1].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent research has increasingly emphasized the importance of addressing modifiable risk factors as a complementary prevention strategy[4].
Hearing loss is the single largest modifiable risk factor for dementia globally, with a population attributable fraction (PAF) of approximately 7%. This finding emerges from the 2024 Lancet Commission update on dementia prevention, which identified 14 modifiable risk factors that together account for nearly half of all dementia cases[5].
Prevalence and Impact:
Mechanisms Linking Hearing Loss to Cognitive Decline:
Cortical Atrophy: Reduced auditory input leads to structural changes in auditory cortex and downstream brain regions. Functional MRI studies show decreased activation in auditory processing areas in individuals with hearing loss.
Increased Cognitive Load: Effortful listening requires significant cognitive resources, diverting attention and working memory capacity from other cognitive tasks. This chronic cognitive "overload" may accelerate cognitive decline.
Social Withdrawal: Hearing loss often leads to social isolation and reduced engagement in cognitively stimulating activities. Social isolation is itself an independent risk factor for dementia.
Brain Structural Changes: Studies show greater rates of brain atrophy in auditory and cognitive regions in individuals with hearing loss, particularly in the temporal lobe and hippocampus.
Altered Brain Network Connectivity: Hearing loss is associated with changes in functional connectivity between auditory and prefrontal brain regions, affecting attention and executive function.
The original ACHIEVE randomized controlled trial (published 2023) enrolled 977 older adults aged 60-79 with hearing loss but no significant cognitive impairment. Participants were randomized to either:
Key Findings[2:1]:
Interpretation: The ACHIEVE trial provides the first randomized controlled trial evidence that addressing hearing loss can meaningfully slow cognitive decline. The result has been described as a "paradigm shift" in dementia prevention, highlighting the potential of non-pharmacological interventions.
This follow-up study extends the observation period to examine:
This is a Phase 3 observational follow-up study building on the original randomized ACHIEVE trial. Phase 3 trials represent the final stage of clinical evaluation and are designed to demonstrate therapeutic efficacy in large patient populations[6].
Key features of the ACHIEVE follow-up study include:
The parent trial was a randomized, controlled clinical trial with the following structure:
Global cognition is assessed using a comprehensive neuropsychological battery including:
Brain MRI measures:
Hearing-specific measures:
Functional measures:
Biomarker correlates (in subset):
This clinical trial represents a critical step in the development of preventive strategies for Alzheimer's disease[7]:
Paradigm shift: Demonstrates that non-pharmacological interventions targeting modifiable risk factors can significantly impact cognitive decline
Public health impact: Hearing loss affects over 60% of older adults; if proven effective, hearing intervention could prevent millions of dementia cases globally
Cost-effectiveness: Hearing aids are relatively low-cost compared to pharmacological treatments; successful results could support reimbursement policies
Integration of care: Highlights the importance of integrating hearing healthcare into cognitive care pathways for older adults
Mechanistic insights: MRI and biomarker data will illuminate how hearing intervention protects brain structure and function
| Intervention | Target | Population | Effect Size |
|---|---|---|---|
| Hearing intervention | Modifiable risk factor | At-risk older adults | 48% reduction in cognitive decline |
| Aerobic exercise | Physical activity | Older adults | 28-45% risk reduction |
| Mediterranean diet | Dietary | Midlife adults | 35% risk reduction |
| Cognitive training | Cognitive reserve | Older adults | Modest effects |
The ACHIEVE results represent one of the largest effect sizes observed in dementia prevention trials, rivaling pharmacological approaches.
The hearing intervention in ACHIEVE includes multiple components:
Audiological Evaluation:
Hearing Aid Selection:
Fitting and Verification:
Rehabilitation:
Modern hearing aids used in ACHIEVE include:
| Feature | Benefit | Application |
|---|---|---|
| Directional microphones | Focus on speech | Social settings |
| Noise reduction | Comfort | Noisy environments |
| Feedback suppression | Stability | Phone use |
| Wireless streaming | Clarity | Media |
| AI processing | Optimization | Complex settings |
Hearing aid adherence is critical:
The neuroimaging component includes:
Structural MRI:
Advanced Sequences:
Key regions of interest:
| Region | Clinical Significance | Expected Change |
|---|---|---|
| Hippocampus | Episodic memory | 1-2%/year (AD) |
| Entorhinal cortex | Early tau | Sensitive to change |
| Whole brain | Global atrophy | 0.5-1%/year |
| White matter | Vascular changes | Hyperintensity increase |
| Auditory cortex | Hearing deprivation | Activity change |
Resting-state networks assessed:
Expected changes in AD:
Hearing loss increases cognitive load:
Hearing impairment
↓
Increased effort for speech perception
↓
Diverted cognitive resources
↓
Reduced reserve for memory/attention
↓
Accelerated cognitive decline
Evidence:
MRI evidence for protection:
Possible mechanisms:
Hearing intervention promotes:
Social isolation risk factors:
Mixed-effects model:
Intent-to-treat (ITT):
Original trial:
Follow-up extension:
Multiple imputation for:
Sensitivity analyses:
Components evaluated:
Utilities measured:
Expected results:
| Subgroup | Hypothesis | Expected Effect |
|---|---|---|
| High-risk | Baseline factors | Larger benefit |
| Older age | Age-related vulnerability | Moderate benefit |
| Severe hearing loss | Greater need | Larger benefit |
| Women | Sex differences | Similar/moderate |
| ApoE+ | Genetic risk | Variable |
Challenges to widespread implementation:
Successful results support:
Considering low/middle-income countries:
Emerging technologies:
Potential multi-domain approaches:
Template for future:
Novel therapeutic approaches for neurodegenerative diseases (2024). 2024. ↩︎
ACHIEVE randomized trial of hearing intervention. 2023. ↩︎ ↩︎
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23). 2023. ↩︎ ↩︎
Amyloid cascade hypothesis: time for a reappraisal (2023). 2023. ↩︎
Hearing loss and cognitive decline in older adults. 2023. ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎